ISAL 2019 | Oral arsenic for the treatment of APL in China
Hong-Hu Zhu, MD, PhD, of The First Affiliated Hospital, Zhejiang University, Hangzhou, China, discusses the use of oral arsenic for the treatment of acute promyelocytic leukemia (APL) in China. Previous intravenous formulations of arsenic trioxide and all-trans retinoic acid (ATRA) meant that patients were required to visit the hospital for treatment. Now patients can complete post-remission treatment at home, greatly improving their quality of life. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
Get great new content delivered to your inboxSign up